Plasma amyloid b-42 (Ab42) and Ab42/Ab40 are increasingly recognized as biomarkers for dementia, with low levels indicating increased risk. Little is known about the demographic and medical correlates of plasma Ab40 or Ab42. In 997 community-dwelling, nondemented older adults from the Health, Aging, and Body Composition Study, we determined the cross-sectional association between a wide range of demographic and medical variables with Ab40 and Ab42. In multivariate stepwise linear regression models, Ab40 was significantly associated with race (b = À14.70, F = 22.01, P < 0.0001), age (b = 1.34, F = 6.39, P = 0.01), creatinine (b = 52.91, F = 151.77, P < 0.0001), and the serum brain-derived neurotrophic factor (b = À0.0004, F = 7.34, P = 0.007); Ab42 was significantly associated with race (b = À3.72, F = 30.83, P < 0.0001), sex (b = 1.39, F = 4.32, P = 0.04), education (b = 1.50, F = 4.78, P = 0.03), apolipoprotein E e4 genotype (b = À 2.82, F = 16.57, P < 0.0001), and creatinine (b = 9.32, F = 120.09, P < 0.0001). These correlates should be considered as potential confounders in future studies investigating plasma Ab as a biomarker of dementia. Understanding fully how these correlates mediate or modify the association between plasma Ab and dementia will be a fundamental step in determining the biological pathways through which plasma Ab40 and Ab42 are associated with dementia, and in determining their full potential as biomarkers. APOE indicates apolipoprotein E; Ab40, amyloid b-40; Ab42, amyloid b-42; BDNF, brain-derived neurotrophic factor.
R ecent studies have indicated that plasma amyloid b-40 (Ab40), Ab42, and the ratio (Ab42/Ab40) may be promising biological markers for cognitive impairment or dementia in older adults. For example, decreased plasma Ab42 was shown to be associated with an increased risk for developing Alzheimer disease (AD) and increased cognitive decline over time. [1] [2] [3] [4] Similarly, a prospective longitudinal study found that low plasma Ab40 was associated with incident AD in older men. 5 Low Ab42/Ab40 has also been associated with increased cognitive decline over time among nondemented elders and with increased risk for AD. 1, 6 These 2 proteins are of interest because they accumulate in the brain, forming the plaques found in AD patients. Furthermore, these proteins have been well established as biomarkers for AD when measured from cerebrospinal fluid (CSF) samples. For example, CSF Ab42 declines in patients with incident dementia, and has been documented as one of the most sensitive biomarkers for detecting prevalent AD. 7, 8 Similarly, some studies have shown that low CSF Ab40 is associated with mild cognitive impairment (MCI) or the early stages of dementia. 9 The possibility of identifying Ab as a useful biomarker from plasma is clinically important because a simple blood draw is much less invasive and less expensive than the lumbar puncture required to obtain CSF.
In spite of this ongoing research, little is known about the general demographic and medical correlates of plasma Ab40 and Ab42, and how the correlates may impact the relationship between plasma Ab and cognitive decline. This information is important for these proteins to be fully understood as biomarkers, and so future studies investigating the potential use of plasma Ab40 and Ab42 as biomarkers for cognitive decline can measure and account for all potential confounders. Furthermore, understanding what factors are related to plasma Ab40 and Ab42 may shed some light on the mechanisms underlying an association between plasma Ab and cognitive function. Importantly, 1 previous study has investigated the correlates of plasma Ab, but the study population consisted of only 205 cognitively normal controls, whereas the remaining sample was comprised of patients with MCI (n = 348) or AD (n = 162). 10 As previous studies have shown that plasma Ab levels change at different stages of disease progression, 11, 12 more studies are needed to investigate the correlates of these markers in community-dwelling, nondemented older adults. Thus, the objective of this study is to describe the demographic and medical correlates of plasma Ab40 and Ab42 in a population of community-dwelling, nondemented, black and white older adults, age 70 to 79 years, at baseline.
METHODS

Study Population
Community-dwelling white and black older adults were enrolled in the ongoing Health, Aging, and Body Composition (Health ABC) study. This prospective cohort study began in 1997, and adults ranged in age from 70 to 79 years at enrollment, and lived in Memphis, TN, or Pittsburgh, PA. Participants were recruited from a random sample of Medicare-eligible adults living within the designated zip codes, and were eligible if they reported no difficulties performing activities of daily living, walking a quarter mile, or climbing 10 steps without resting. They also had to be free of life-threatening cancers, and plan to remain within the study area for at least 3 years. 13 Plasma Ab42 and Ab40 were measured in a random sample of 1000 sexstratified and race-stratified participants. Of those, 3 had incomplete plasma amyloid data because of insufficient amounts of stored blood or measurement error; thus, our analytic cohort was comprised of 997 participants. All participants included in this analytic cohort were free of cognitive impairment at baseline; consistent with previous literature, cognitive impairment was defined as a Modified Mini-Mental Status Exam (3MS) score <80. 14 Compared with Health ABC participants who did not have plasma Ab measured, those in the subgroup were more likely to be black, female, and to have lower mean education, but did not differ on other characteristics. This study was approved by the institutional review boards of the University of Pittsburgh and the University of Tennessee, Memphis, and that of the Coordinating Center, the University of California, San Francisco. All participants signed a written informed consent.
b Amyloid
Stored plasma obtained at the first Health ABC follow-up visit was used to measure Ab40 and Ab42. Plasma was stored at À 701C at Fisher BioServices Inc. Laboratories, and shipped directly to the analytical laboratory. Plasma Ab was measured at the laboratory of Dr Steven Younkin at the Mayo Clinic using Innogenetics INNO-BIA assays. The detection limit for this assay is 12 pg/mL for Ab40 and 5 pg/mL for Ab42. The mean interassay coefficient of variation was 9.9% for Ab40 and 9.3% for Ab42 and the mean intra-assay coefficient of variation was 3.5% for Ab40 and 2.3% for Ab42. Consistent with previous literature, tertile cutoffs were used to categorize Ab42 and Ab42/Ab40 into "low," "medium," and "high" groups.
Potential Correlates
At baseline, demographic data including self-reported participant age, race, sex, and education were recorded. Literacy was measured at baseline with the Rapid Estimate of Adult Literacy in Medicine. 15 Rapid Estimate of Adult Literacy in Medicine scores were categorized as reighth grade and >eighth grade, as it has been reported that this cutoff differentiates those who are functionally illiterate from those who are literate in a health care setting. 16, 17 Cognitive function at baseline was measured with the 3MS. The 3MS is an assessment of global cognitive function with components for orientation, concentration, language, praxis, and immediate and delayed memory. 18 Social support scores were based on the average frequency of visits per week with friends, neighbors, and relatives. Scores were dichotomized into 2 groups: <the median or Zthe median. Self-reported information on smoking history was recorded and dichotomized into never versus ever having smoked.
Prevalent disease algorithms based on both self-report and physician diagnoses, recorded medications, and laboratory data were used to create comorbidity variables indicating the presence of diabetes mellitus, hypertension, stroke or transient ischemic attack (TIA), and myocardial infarction (MI). The Center for Epidemiologic Studies Depression Scale was used to assess depressive symptoms with a score Z16 consistent with possible depression. 19 The body mass index (BMI) (kg/m 2 ) was calculated from direct height and weight measurements at baseline. The physical activity level was determined using a standardized questionnaire designed specifically for the Health ABC study, which has been described previously. 20 Total physical activity, including household chores, paid work, volunteer work, care giving, stair climbing, nonexercise walking, walking for exercise, and other moderate and vigorous exercise activities, was measured in kcal/wk. 20 The apolipoprotein E (APOE) e4 allele status was determined using standard single-nucleotide polymorphism genotyping techniques, and was dichotomized into having Z1 APOE e4 alleles versus no allele. 21 Brain-derived neurotrophic factor (BDNF) was measured from frozen serum collected at the first follow-up visit. Assays were performed by R&D Systems' Analytical Testing Service, using their own commercial kit, using an enzyme-linked immunosorbent assay (ELISA) method. The detection limit for this assay is 1250 pg/mL. The mean interassay coefficient of variation is 9.0%, and the mean coefficient of variation within the assay is 5.0%.
At baseline, low-density lipoprotein cholesterol (LDL) (mg/dL), high-density lipoprotein cholesterol (HDL) (mg/ dL), total cholesterol (mg/dL), and triglycerides (mg/dL) were measured from fasting blood serum. Measures of high-sensitivity C-reactive protein (CRP), tumor necrosis factor-a (TNFa), interleukin-6 (IL-6), and creatinine were obtained from frozen serum or plasma collected at baseline after an overnight fast. Samples were frozen at À 701C and were shipped to the Core Laboratory at the University of Vermont. 22, 23 The serum CRP was measured in duplicate by an ELISA on the basis of purified protein and polyclonal anti-CRP antibodies, and assays were standardized according to the World Health Organization First International Reference Standard with a sensitivity of 0.08 mg/ mL. 22 Plasma IL-6 and TNFa were measured in duplicate by ELISA kits from the R&D Systems (Minneapolis, MN). 24 The detectable limit for IL-6 was 0.10 pg/mL and for TNFa was 0.18 pg/mL. 24 Creatinine was measured with the colorimetric technique on a Johnson & Johnson VITROS 950 Chemistry Analyzer (Johnson & Johnson, New Brunswick, NJ) using the enzymatic method. 23 
Statistical Analyses
To describe the distribution of plasma Ab40 and Ab42, a variety of descriptive statistics were calculated including assessment of the mean, median, range, and SD. The relationship between Ab40 and Ab42 was examined using Spearman correlation coefficient. Fisher exact, Pearson w 2 , and t tests were used, as appropriate, to determine the association between plasma Ab40 and Ab42 tertile and baseline participant characteristics. Finally, stepwise multivariate linear regression models were examined for both Ab40 and Ab42 to determine which characteristics predicted the plasma level independently. Variables that were associated in bivariate analyses (P < 0.10) with Ab40 or Ab42, respectively, were considered for these models. We used a forward stepwise selection process with variables significant at the P = 0.15 entry and exit criteria to determine the final multivariate models. The relative strength of the associations was expressed as an absolute difference in units of change chosen to approximate 1 SD in the distribution for each continuous variable or null category for dichotomous variables, similar to previous studies investigating correlates of markers in older adults. 25, 26 The formula used to calculate the absolute difference in the rate of change in plasma Ab per unit change (SD) of the independent variable was b* = unstandardized bÂunit change in independent variable. The corresponding 95% confidence intervals were calculated using the following formula: b ± (1.96ÂSE)Âunit change. All statistical analyses were performed using SAS version 9.1 (SAS Institute Inc., Cary, NC).
RESULTS
Among the 997 community-dwelling older adults, the means (SD) of Ab40 and Ab42 were 191.6 pg/mL (50.3) and 33.9 pg/mL (9.6), respectively. The median of Ab40 was 192.5 pg/mL and of Ab42 was 32.8 pg/mL. The Spearman correlation coefficient was 0.51 (P < 0.0001) for both markers as continuous variables, and 0.42 (P < 0.0001) for both markers with tertile cutoffs.
Those with a low plasma Ab40 were significantly younger (73.6 ± 3.0 y for low tertile vs. 74.5 ± 2.9 y for high tertile, P = 0.0001), more likely to have less than a highschool education [N (%), 223 (67.2%) vs. 197 (59.5%), P = 0.03], to be black [201 (60.4%) vs. 147 (44.1%), P < 0.0001], to have lower serum creatinine (1.0 ± 0.2 vs. 1.2 ± 0.5 mg/dL, P < 0.0001), to have higher HDL cholesterol (56.6 ± 17.7 vs. 52.9 ± 16.5 mg/dL, P = 0.02), to have higher BDNF (23361.6 ± 10648.3 vs. 20944.4 ± 10022.9 pg/ mL, P = 0.006), and to have lower TNFa (3.3 ± 2.1 vs.
3.7 ± 1.7 pg/mL, P = 0.0007) ( Table 1 ). There were no differences of Ab40 by sex, literacy, baseline 3MS scores, social support, physical activity, history of stroke/TIA, diabetes history, MI, BMI, depressive symptoms, APOE e4 allele status, CRP, IL-6, total cholesterol, LDL cholesterol, triglycerides, or smoking history.
Those with a low plasma Ab42 were more likely to be female [196 (59.8%) vs. 183 (55.5%), P = 0.05], to have less than a high-school education [231 (70.6%) vs. 193 (58.8%), P = 0.006], to be black [214 (65.2%) vs. 151 (45.8%), P < 0.0001], to have a history of diabetes [94 (29.8%) vs. 68 (21.3%), P = 0.04], to have at least 1 APOE e4 allele [118 (38.3%) vs. 73 (23.1%), P = 0.0002], to have lower creatinine (1.0 ± 0.2 1.1 ± 0.6 mg/dL, P < 0.0001), to have greater social support [179 (54.6%) vs. 154 (46.7%), P = 0.05], and to have higher HDL cholesterol (57.3 ± 17.9 vs. 53.5 ± 16.9 mg/dL, P = 0.007) ( Table 2 ). There were no differences in Ab42 by age, literacy, baseline 3MS scores, physical activity, history of stroke/TIA, MI, BMI, depressive symptoms, CRP, TNFa, IL-6, BDNF, total cholesterol, LDL cholesterol, triglycerides, or smoking history.
In a stepwise multivariate linear regression model, Ab40 was significantly associated with age (b = 1.34, F = 6.39, P = 0.01), race (b = À14.70, F = 22.01, P < 0.0001), creatinine (b = 52.91, F = 151.77, P < 0.0001), and BDNF (b = À0.0004, F = 7.34, P = 0.007) (Table 3) . Similarly, Ab42 was significantly associated with race (b = À 3.72, F = 30.83, P < 0.0001), sex (b = 1.39, F = 4.32, P = 0.04), education (b = 1.50, F = 4.78, P = 0.03), APOE e4 allele status (b = À 2.82, F = 16.57, P < 0.0001), and creatinine (b = 9.32, F = 120.09, P < 0.0001) ( Table 3 ). The strength of the associations expressed as an absolute difference in units of change (1 SD for continuous variables or null category for dichotomous variables) are shown in Table 4 . Age, race, creatinine, and BDNF were all significant correlates of Ab40; race, sex, education, APOE e4, and creatinine were all significant correlates of Ab42, although sex and education were borderline (Table 4 ).
DISCUSSION
Our results indicated that plasma Ab40 and Ab42 are fairly normally distributed among older adults without dementia. Furthermore, our results suggested that in a community-dwelling sample of white and black older adults, plasma Ab40 significantly differed by age, race, education, serum creatinine, serum BDNF, HDL cholesterol, and the inflammatory marker TNFa. Similarly, plasma Ab42 was significantly associated with race, sex, education, social support, a history of diabetes, HDL cholesterol, serum creatinine, and APOE e4 genotype.
Our results are supported by prior indirect associations between demographic and medical risk factors and AD. For example, we found that black race was associated with significantly lower levels of plasma Ab40 and Ab42, and being female was significantly associated with a lower level of Ab42. As it has been shown that African Americans and females have an increased risk of AD, and other studies have shown that low Ab42 is associated with increased risk of dementia, these results seem consistent. 4, 27 Our results showing an association between diabetes and plasma Ab42 are in support of earlier studies suggesting that consistently increased insulin levels in the brain may lead to increased Ab42 deposition and plaque formation, and subsequent decreases in peripheral plasma Ab42. 28, 29 Our results differ from another longitudinal study that recently found that higher total cholesterol and higher LDL cholesterol predicted a low plasma Ab42. 30 Furthermore, this previous study found no association between HDL cholesterol and Ab42 at baseline or over time, as we did with plasma Ab40 and Ab42. 30 Similarly, we found no association of Ab40 or Ab42 with LDL, total cholesterol, triglycerides, or a history of MI or strokeboth of which have high cholesterol as a common risk factor. Finally, the association we found between both plasma Ab40 and Ab42 and serum creatinine-a measure of renal function-is supported by another study, which found that in older patients with chronic renal failure, dialysis significantly lowered the plasma Ab42 level; these results indicate that a close relationship may exist between renal function and plasma Ab42. 31 It is widely known that the APOE e4 allele is associated with an increased risk for AD, and in this study, we found that older adults with at least 1 APOE e4 allele were more likely to have a low Ab42; APOE has also been shown to modify the association between Ab42 and Ab42/Ab40 and cognitive decline. 6, 32 An interesting finding was the association between higher serum BDNF and a low plasma Ab40. BDNF is thought to have neuroprotective effects and to promote brain plasticity. 33 BDNF has also been shown to regulate the amyloid precursor protein, which is thought to reduce the production of amyloid peptides (ie, Ab40). 33 Thus, it is possible that higher levels of serum BDNF may, at least in part, regulate plasma Ab40, resulting in the lower plasma Ab40 level. There was no relationship found between plasma Ab42 and serum BDNF. The inflammatory marker TNFa has been shown to be associated with increased risk of cognitive decline over time. 34 Although we found an association between low TNFa and low plasma Ab40, which is in contrast to what we expected, we believe that this could be due to the less specific association between Ab40 and AD or cognitive decline (vs. the relationship between Ab42 and cognitive function). 34 Importantly, our results are also supported in part by a previous study investigating the correlates and predictors of plasma Ab in a population of cognitively normal, MCI and AD patients. 10 Both studies reported relatively normal distributions of both plasma Ab40 and Ab42, indicating no need to log-transform plasma Ab40 or Ab42 when analyzing them as continuous variables, although it was reported that the ratio needed log transformation. 10 Furthermore, both studies found significant associations between higher Ab40 and Ab42 and poorer kidney function in t tests, and found that creatinine significantly predicted both markers. 10 Other similarities were significant associations between age and Ab42, APOE and Ab42, and cholesterol and Ab40. 10 This study did not support our findings in that it found no association between education or race and either plasma marker; in models, the most significant predictors of Ab40 and Ab42 were creatinine, total proteins, and cholesterol, whereas our results showed different significant predictors of Ab42 and Ab40. 10 Interestingly, in the other study, age, education, or APOE e4 did not significantly predict either marker as we found, and these are known strong risk factors for AD. 10 Finally, the prior study found a much stronger correlation between plasma Ab40 and Ab42 (r = 0.83 vs. r = 0.51). 10 We believe that the differences are most likely attributable to different populations, as our study was made up of community-dwelling older adults who were all dementia free, compared with a population of primarily MCI and AD patients with only a small proportion of cognitively normal controls. 10 Given these characteristics, the contrasting results could reflect that disease progression largely affects plasma Ab measurements and correlates. Ultimately, more studies are needed to better understand the fluctuations of plasma Ab40 and Ab42 in older adults, who age without cognitive decline, with MCI and with AD to better understand these relationships.
If plasma Ab40 and Ab42 indeed are useful biomarkers of cognitive decline and dementia, then it is important to fully understand how these biomarkers are influenced by demographic and medical conditions for several reasons. First of all, at a very basic level, it will be important so that future studies can measure and adjust for all potential confounders when investigating the association of plasma Ab to ensure that the most accurate results are presented. Understanding demographic and medical correlates will also be crucial in considering what factors may regulate plasma Ab. This will be critical for gaining a better understanding of the mechanisms underlying cognitive decline and dementia. It will also help in identifying possible targets for interventions in reducing the risk of or preventing dementia.
This study had several strengths, including the large sample size providing ample analytical power for this study. Measurement of numerous potential confounders allowed us to investigate a large number of demographic and medical characteristics in 1 sample. Finally, Innogenetics INNO-BIA assays were used for our measurements of Ab42 and Ab40, and this method may provide more accurate measurements of Ab42 and Ab40 because of its high sensitivity, low variability, and high reproducibility. 35 There are also several weaknesses that should be taken into consideration when interpreting these results. These adults were all well functioning and community dwelling at baseline, and so the results may not be generalizable to all older adults-for example, nursing home populations. Another potential weakness is that we did not have CSF measurements of Ab, and thus, we could not correlate plasma Ab to measurements of CSF Ab. As CSF Ab has been such a well-established biomarker for dementia, it would have been useful.
This study identified the demographic and medical correlates of plasma Ab40 and Ab42. The correlates identified in this paper should be considered in future studies as potential confounders of the association between plasma Ab and cognitive decline or dementia. Understanding fully how these correlates mediate or modify the association between plasma Ab and dementia will be a fundamental step in determining the biological pathways through which plasma Ab contributes to dementia and cognitive decline. Future studies should continue to investigate exactly how these demographic and medical correlates may influence the relationship between plasma Ab40 and Ab42, as it may help us target interventions for preventing and reducing the risk of AD and dementia.
